Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
356
resultados
Última actualización
04/10/2026 [07:34:00]
Resultados 100 a 125 de 356
Resumen de: CN122731053A
本发明公开了一种多功能的多模态串联质谱标签及其在化学蛋白质组学定量中的应用。所述标签包含亲和富集模块、可断裂连接模块和等量异位标签模块，其中等量异位标签模块整合有报告基团、质量平衡基团和生物正交反应把手。该标签具有全新的等量异位标签骨架，不含氨基反应活性基团，避免了赖氨酸侧链误标记；末端炔基可通过一步点击化学反应与叠氮标记的肽段连接，实现化学蛋白质组学流程中富集、释放和定量功能的一体化安装。实验表明，本发明标签在二级质谱中可稳定释放报告离子，报告离子信号强度比与标记肽段混合比例高度一致，在10倍差异范围内定量准确。本发明简化了化学蛋白质组学定量操作，减少样本损失，提高了定量的准确性和便捷性。
Resumen de: AU2025226972A1
The invention pertains to treating a cognitive impairment, for example, an aging-associated cognitive impairment. In certain aspects, a sample obtained from a subject is assayed for the ratio between the levels of any two proteins selected from: DLL1, SMOC1, CD59, TSTD1, STAT3, POLD4, PARP11, LEFTY2, UNC5B, C5, C5.C6, ASH2L, INHBB, RSP3, VAV3, SIRT3 and SERPINB8. A subject may be having or suspected of having a cognitive impairment. The cognitive impairment can be caused by a neurodegenerative disease, such as Alzheimer's disease. A subject may be identified as likely or not likely to respond positively to the plasma exchange therapy based on the ratio between the levels of measured proteins. In certain aspects, methods for treating a cognitive impairment in the subject comprise administering a plasma exchange therapy comprising a full and/or low volume plasma exchange. Also provided are kits suitable for performing such methods.
Resumen de: WO2025177848A1
The present invention addresses the problem of providing: a biomarker for determining cognitive impairment or nerve function disorder in an early stage with high accuracy; and others. In the present invention, a drebrin metabolite peptide (iMADP) selected from the below-mentioned peptides (i) to (iii) is used as a biomarker for determining cognitive impairment or nerve function disorder. (i) A peptide comprising the amino acid sequence represented by SEQ ID NO: 4; (ii) a peptide comprising the amino acid sequence represented by SEQ ID NO: 5; and (iii) a peptide which comprises an amino acid sequence having a structure such that one or more amino acid residues are deleted, substituted, and/or added in the amino acid sequence represented by SEQ ID NO: 4 or SEQ ID NO: 5.
Resumen de: CN122731161A
0001 本发明提供了一种检测褪黑素的体外微针贴片及其制备方法和应用，涉及生物医用材料和器械技术领域。本发明检测褪黑素的体外微针贴片的制备方法，包括以下步骤：固体微针贴片用2~100μg/mL兔抗人褪黑素IgG溶液进行蛋白包被，得检测褪黑素的体外微针贴片；所述固体微针贴片先经表面亲水修饰或不经表面亲水修饰，所述表面亲水修饰包括等离子处理。本发明制备方法能够使得体外微针贴片定量检测微量的、特定的褪黑素蛋白，具有高灵敏度、高准确性。
Resumen de: US20260265825A1
0000 A signature for identifying a subject at risk of developing a severe reaction to a SARS-CoV virus by detecting one or more of elevated serum cytokines, reduced monocyte subclasses, differentially expressed genes in monocyte subclasses, differentially expressed gene in CD8+ effector memory T cells, and elevated chromatin accessibility in intermediate monocytes are disclosed herein. Also disclosed are methods for obtaining the signature, methods of identifying a subject at risk of developing a severe reaction to a SARS-CoV virus, and methods of treating COVID-19.
Resumen de: US20260264076A1
0000 A multiplexed capillary-flow immunoassay device configured for the simultaneous detection of multiple analytes, specifically, a testing assembly including a detection area, a fluid inlet, and a microfluidic network including at least two microfluidic pathways directed to distinct detection areas each configured to detect a different analyte.
Resumen de: AU2026204971A1
The present disclosure generally relates to a cell culturing system, and specifically to a three-dimensional cell culturing system for neuronal cells that promotes both structural and functional characteristics that mimic those of in vivo peripheral fibers, including cell myelination. Using a dual hydrogel construct and spheroids comprising neuronal cells, the present disclosure provides methods, devices, and systems for in vitro spatially-controlled, three-dimensional models that permit intra- and extra-cellular electrophysiological measurements and recordings. The three-dimensional hydrogel constructs allow for flexibility in incorporated cell types, geometric fabrication, and electrical manipulation, providing viable systems for culture, perturbation, and testing of biomimetic neural growth with physiologically-relevant results. BSTRACT
Resumen de: US20260266850A1
0000 Methods, compositions and kits useful in the detection, assessment, diagnosis, prognosis and/or treatment of neurological injury or disease or brain injury, such as traumatic brain injury (TBI), are provided in which certain newly discovered protein biomarkers are detected in a biological sample of a subject undergoing testing or evaluation. The methods allow for detection of changes in levels, amounts, or concentrations of the protein biomarkers in a subject compared with those of controls. Detection of the protein biomarkers, and/or levels thereof, provides an indication of biological and biochemical events, e.g., at a cellular level, that are occurring in the subject who is undergoing testing or analysis for the neurological injury or brain injury.
Resumen de: US20260265838A1
0000 Methods of deconvolving a feature profile of a physical system are provided herein. The present method may include: optimizing a regression between a) a feature profile of a first plurality of distinct components and b) a reference matrix of feature signatures for a second plurality of distinct components, wherein the feature profile is modeled as a linear combination of the reference matrix, and wherein the optimizing includes solving a set of regression coefficients of the regression, wherein the solution minimizes 1) a linear loss function and 2) an L2-norm penalty function; and estimating the fractional representation of one or more distinct components among the second plurality of distinct components present in the sample based on the set of regression coefficients. Systems and computer readable media for performing the subject methods are also provided.
Resumen de: US20260265411A1
0000 Isolated histidyl-tRNA synthetase splice variant polynucleotides and polypeptides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
Resumen de: US20260263440A1
0000 Described are processes for the production of a composition comprising (2R, 3R, 4R, 5S)-3, 4, 5-trihydroxypiperidine-2-carboxylic acid (idoBR1), said process comprising the steps of: a) providing plant material from a botanical source comprising plant of the family Cucurbitaceae; b) fractionating said plant material to produce an extract enriched in idoBR1 c) assaying said extract for: i) inhibitory activity against sialidase or TNF-alpha or ii) IL-10 stimulatory activity; and d) formulating said assayed extract with a cosmetically-, nutraceutically- or pharmaceutically-acceptable excipient or carrier to produce a cosmetic, nutraceutical or pharmaceutical composition.
Resumen de: US20260266800A1
Systems, devices, and methods herein may include a system for monitoring bodily fluid from a patient. In some embodiments, the system may be configured to collect bodily fluid samples from a patient periodically over time to determine a baseline bodily fluid composition. In some embodiments, the system may use spectrophotometry to determine the baseline bodily fluid composition for the patient. The system may be configured to compare a bodily fluid sample to the baseline bodily fluid composition to detect detecting changes in one or more characteristics of the bodily fluid sample (e.g., composition, absorption spectrum, etc.) from the baseline. Changes in the bodily fluid sample characteristics may be used to predict and/or detect abnormalities or infection for individualized diagnosis.
Resumen de: WO2026188004A1
Provided are methods for determining the risk or monitoring the progression of Alzheimer's disease in a subject using expression levels of one or more circRNAs. Also provided are methods for treating a subject identified as having or at risk for Alzheimer's disease.
Resumen de: US20260265806A1
Embodiments of the instant disclosure relate to early diagnosis and intervention and/or treatment of neurodegenerative disorders and/or brain damage due to normal aging. Certain embodiments disclosed herein relate to quantifying concentrations of ubiquitin c-terminal hydrolase L1 (UCH-L1) in samples obtained from a subject to assess neuronal cell health and/or diagnose the subject with age-related neuronal cell damage. In some embodiments, a subject can be treated with an effective amount of a therapeutic to stabilize and/or reduce concentrations of UCH-L1 in the subject and treat the subject. In other embodiment, a targeted therapeutic agent, process, or task can be assessed for efficacy of reversing brain aging in a subject.
Resumen de: WO2026187868A1
The present disclosure provides specific anti-ac-tauK174, anti-ac-tauK274, and ac-tauK353 antibodies, or antigen-binding fragments thereof, and methods of their use in diagnosing, differentiating, targeting, staging, prognosing, and/or treating Alzheimer's Disease and related tauopathies, including traumatic brain injury. Methods of identifying a subject having early Alzheimer's Disease and related tauopathies are also provided, the methods comprising detecting proteins using at least one anti-ac-tauK174 antibody, at least one anti-ac-tauK274 antibody, and/or at least one anti-ac-tauK353 antibody. In some embodiments, the subject is ApoE4-positive.
Resumen de: US20260265322A1
0000 Disclosed herein include polynucleotides, expression vectors and compositions enabling expression of a self-assembling proteopathic fusion protein comprising a self-assembling domain fused to a proteopathic polypeptide associated with a proteinopathy. The self-assembling proteopathic fusion protein is capable of forming intracellular protein aggregates that enable robust recapitulation of disease pathology. Provided herein also include methods of using the self-assembling systems disclosed herein to induce proteinopathies (e.g., neurodegenerative diseases) and to screen therapeutic compounds for the treatment of proteinopathies.
Resumen de: WO2026187918A1
Provided herein are systems, devices and methods relating to the diagnosis of traumatic brain injury. A mobile application uses a smartphone camera and an on-device artificial intelligence model to read lateral flow assay test strips and produce a concussion diagnostic result. The application determines whether a concussion biomarker is present in a sample and, when present, calculates a numeric intensity score that reflects the strength of the biomarker signal. Before displaying any result, the application automatically checks the image and test for a set of quality and validity conditions and, if any problem is found, tells the user specifically what went wrong and how to correct it. The application guides users through the entire testing process with a step-by-step interface designed to be usable without clinical training, stores all completed results on the device for longitudinal review, and can optionally receive data from a paired hardware lateral flow assay reader.
Resumen de: WO2026187110A1
The present invention relates to a method for customized diagnosis of patients with acyl coenzyme A overproduction and screening for therapeutic agents for acyl coenzyme A overproduction-associated diseases by using a metabolite having a nucleophilic amine group. The present invention provides a method capable of indirectly identifying the degree of acyl coenzyme A overproduction by measuring an acyl-product generated upon ingestion of a metabolite having a nucleophilic amine group, and thus enables customized diagnosis of patients with acyl coenzyme A overproduction and screening for customized therapeutic agents for diseases caused by acyl coenzyme A overproduction.
Resumen de: US20260266849A1
0000 Methods for serial amplification of Tau filaments and Tau assemblies include contacting monomeric Tau protein with Tau seed material under conditions permissive for seed-dependent fibril or assembly growth to produce amplified Tau filaments or assemblies, processing at least a portion of the amplified material to generate Tau seed material for further amplification, and repeating the contacting and processing steps to produce serially amplified Tau filaments or assemblies, where the monomeric Tau includes one or more Tau isoforms, variants, fragments, or modified forms. In some embodiments, Tau seed material is obtained from a biological sample associated with a Tauopathy. The methods further include characterizing amplified Tau filaments or assemblies or using the serial amplification process to identify compounds that modulate Tau assembly propagation by comparing propagation characteristics in the presence and absence of a test compound.
Resumen de: WO2026185475A1
The invention relates to a method for measuring production and/or reduction of the concentration of a chemical species from a microbiota sample of a subject, the method comprising: - preparing a solution to be analysed by adding a buffer solution to a microbiota sample of a subject; - measuring, with a measuring device, a concentration of the chemical species in the solution to be analysed at an initial time in order to obtain a reference measurement of the concentration of the chemical species in the sample at the initial time; then - carrying out multiple successive measurements of the concentration of the chemical species in the solution to be analysed during a determined period in order to establish a data sequence representing the production and/or the reduction of the chemical species in the solution to be analysed over time, wherein the chemical species is chosen from NO and NO 2 -.
Resumen de: WO2026188078A1
The invention relates to quantitative blood-based protein biomarkers and computational methods for detecting and monitoring inner ear disorders and hearing loss. Proteins identified in plasma and extracellular vesicles following noise exposure, ototoxic drug administration, or age-related degeneration are quantified using mass spectrometry, aptamer-based array assays, or immunoassays. Inner ear disorder is identified based on defined fold-change thresholds or multi-biomarker panel performance achieving an AUC of at least 0.75. The invention further provides computer-implemented classification methods and diagnostic kits for early detection and therapeutic monitoring of inner ear disorders.
Resumen de: US20260266814A1
0000 Methods and kits for selectively separating biomolecules in complex samples, such as in blood serum, plasma, and other biological fluids. Metal-organic frameworks (MOFs) are formed around selected biomolecules in a mixture during an in-situ growth process, thereby allowing these biomolecules to be separated more easily from molecules that are not encapsulated by the MOFs. One aspect of the invention separates high-abundance proteins from a biological fluid to enhance the detection and characterization of lower-abundance or harder to detect proteins. This allows the lower-abundance or harder to detect proteins to be more easily detected and accurately analyzed, for example, by mass spectrometry. This is particularly useful in blood samples that contain highly-abundant plasma proteins that interfere with the mass spectrometry analysis of lower-abundant proteins and and protein biomarkers.
Resumen de: WO2026184869A1
The invention relates to using membrane-associated α-synuclein on neuronal-derived extracellular vesicles as a biomarker in the prediction or monitoring of a subject having Parkinson's Disease, and provides methods for determining its level using microfluidics chips.
Resumen de: US20260269021A1
A modular breath analysis system is disclosed for analyzing volatile organic compounds in exhaled breath and correlating measured compound profiles with physiological or pathological states of a subject. The system may include a breath sampling subsystem, a breath conditioning subsystem, a sensor array, and a processing subsystem configured to generate a volatile organic compound profile and apply a correlation model. In some embodiments, a base instrument is configured to receive interchangeable sensing modules through mechanical, fluidic, and electrical interfaces. The sensing modules may include gas sensors, flow-routing structures, filters, membranes, identifiers, calibration data, or combinations thereof. Different sensing modules may be configured for different volatile organic compound panels associated with metabolic conditions, blood glucose estimation, respiratory conditions, infectious diseases, cancer, or other physiological or pathological states.
Nº publicación: WO2026187902A1 10/09/2026
Solicitante:
MASSACHUSETTS GEN HOSPITAL [US]
THE GENERAL HOSPITAL CORPORATION
Resumen de: WO2026187902A1
The present disclosure relates to systems comprising nano-plasmonic chips and methods for the detection of proteins.
BOPI
Sede Electrónica
